Most MS patients currently treated with fingolimod or ocrelizumab will fail to mount an immune response to COVID-19 vaccination, according to the results of the first real-world study of vaccine response in MS patients on disease-modifying therapies (DMT) (Achiron et al. Ther Adv Neurol Disord 2021:14:1-8). An adequate vaccine response was seen in cladribine-treated patients. Read More
Neurology
AAN Daily Reports – Wednesday, April 21 edition
April 21, 2021American Academy of Neurology annual meeting – April 17-22, 2021
Tuesday, April 20 edition
Monday, April 19 edition
CONGRESS HIGHLIGHTS – WEDNESDAY EDITION Read More
AAN 2021 Poster Picks – Day 3
April 21, 2021AAN 2021 Poster Picks – Day 2
AAN 2021 Poster Picks – Day 1
Poster 150 – Characterizing 1-Year Development of Cervical Cord Atrophy Across Different MS Phenotypes: A Voxel-Wise, Multicenter Analysis
Massimo Filippi, MD
Objective: Evaluate the change in cervical cord atrophy over time. Read More
AAN Daily Reports – Tuesday, April 20 edition
April 20, 2021American Academy of Neurology annual meeting – April 17-22, 2021
Wednesday, April 21 edition
Monday, April 19 edition
CONGRESS HIGHLIGHTS – TUESDAY EDITION Read More
AAN 2021 Poster Picks – Day 2
April 20, 2021AAN 2021 Poster Picks – Day 3
AAN 2021 Poster Picks – Day 1
Poster 076 – Long Term Efficacy Outcomes with Inebilizumab Treatment in NMOSD: the N-MOmentum Trial
Bruce A. C. Cree, MD, PhD
Objective: Evaluate the long-term efficacy of inebilizumab in neuromyelitis optica spectrum disorder. Read More